EQL Pharma is a generics- and speciality pharma company, dedicated to providing cost efficient pharmaceuticals for the Nordic markets. This is accomplished with the highest quality standards and streamlined logistic solutions.
EQL Pharma resolves on a rights issue of approximately SEK 24.9 million and announces changed date for publication of the Q2 interim report to 18th October, 2018
The rights issue in brief Pursuant to the authorization resolved by the annual general meeting on August 22nd, 2018, the board of directors of EQL Pharma has today resolved on a rights issue of shares (the “Issue”). Through the Issue,…
Anders Månsson appointed new member of the Board of EQL Pharma AB
Anders Månsson has extensive experience from the pharmaceutical industry and has worked in senior positions in mid-size pharma companies, including Ferring and LEO Pharma. He has worked internationally - from London, Lausanne and Copenhagen, but since last year he has…
Report from the Annual General Meeting of EQL Pharma AB (publ) on August 22nd, 2018
Adoption of the balance sheet and income statement, disposition regarding the Company’s results The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2017-01-01 –…
- View all press releases